1.The feasibility of using high-definition thoracoscopy to identify sympathetic ganglia during thoracic sympathicotomy for primary palmar hyperhidrosis
Gang XU ; Chaoyue HU ; Cong CHEN ; Yuancai LIN ; Daolong ZHU ; Han LIU ; Dong WANG
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery 2026;33(04):578-583
Objective To explore the feasibility of using high-definition thoracoscopy to identify sympathetic ganglia during thoracic sympathicotomy for primary palmar hyperhidrosis. Methods The clinical data of patients with primary palmar hyperhidrosis who underwent high-definition thoracoscopic sympathicotomy in Taikang Xianlin Drum Tower Hospital from June to July 2023 were retrospectively analyzed. Intraoperative visualization rates and anatomical variations of sympathetic ganglia were recorded, and the consistency between white-light thoracoscopy and near-infrared fluorescence imaging was compared. Additionally, surgical videos from previous fluorescence-guided procedures were reviewed. Results Finally 100 patients were collected, including 54 females and 46 males, with an average age of (21.92±6.56) years. All patients underwent endoscopic thoracic sympathicotomy at R3 level. The overall intraoperative ganglion visualization rate was 92.5% (740/800), with G2-G5 rates of 95.5% (191/200), 94.0% (188/200), 94.0% (188/200), and 86.5% (173/200), respectively. Ganglion variations occurred in 32.0% (237/740), predominantly at G3 (29.8%) and G4 (42.6%). In 5 indocyanine green-enhanced patients, the concordance rate between white-light and near-infrared fluorescence imaging was 100.0% (38/38). Video analysis of 14 near-infrared fluorescence-guided surgeries demonstrated a 99.1% (107/108) consistency rate. Postoperative palmar hyperhidrosis improvement reached 100.0% (100/100) with no Horner’s syndrome. Conclusion With the wide clinical application of high-definition thoracoscopy, accurate thoracic sympathicotomy has the feasibility of clinical application.
2.Swine TRIM25 inhibits vesicular stomatitis virus replication by activation of type I IFN signaling pathway and binding vRNA
Ying CAO ; Jinxia ZHANG ; Dongwan YOO ; Haowen ZHANG ; Dandan JIANG ; Yue HU ; Xiaoyan CONG ; Juntong LI ; Xiangju WU ; Yijun DU ; Jing QI ; Juan HUANG
Journal of Veterinary Science 2026;27(3):e25-
Objective:
To define the mechanism by which swine TRIM25 restricts vesicular stomatitis virus replication.
Methods:
Porcine 3D4/21 cells with TRIM25 overexpression or knockdown were infected with vesicular stomatitis virus. Viral replication was quantified by immunoblotting, quantitative reverse transcription polymerase chain reaction, and 50% tissue culture infectious dose assays. Type I interferon signaling was assessed by transcript quantification, interferon-beta and interferon-stimulated response element reporter assays, and co-immunoprecipitation.Viral RNA binding was tested by RNA immunoprecipitation.
Results:
TRIM25 overexpression reduced viral RNA and infectious titers, whereas TRIM25 knockdown increased replication (p < 0.01). TRIM25 increased interferon-beta and interferon-stimulated gene expression and enhanced interferon-beta and interferonstimulated response element promoter activity (p < 0.01). Mechanistically, TRIM25 promoted Lys63-linked ubiquitination of RIG-I and increased phosphorylation of TANK-binding kinase 1 and interferon regulatory factor 3. TRIM25 also bound vesicular stomatitis virus genomic RNA, and binding required the C-terminal region.
Conclusions
and Relevance: Porcine TRIM25 restricts vesicular stomatitis virus replication by amplifying type I interferon signaling and directly binding viral RNA.
3.WANG Yaoxian's Experience in Treating Diabetic Kidney Disease from the Perspective of Spleen and Stomach:Based on the Theory of "Internal Heat Leading to Concretions"
Bo ZHANG ; Yuxin HU ; Cong ZHAO ; Jiale ZHANG ; Weimin JIANG ; Chang YU ; Yang LIU ; Liqiao SUN ; Weiwei SUN ;
Journal of Traditional Chinese Medicine 2026;67(5):482-486
This paper summarizes Professor WANG Yaoxian's experience in treating diabetic kidney disease (DKD) from the perspective of spleen and stomach based on the "internal heat leading to concretions" theory. It is considered that internal heat leading to concretions constitutes the core pathogenesis of DKD, with the spleen and stomach serving as the source of internal heat; therefore, treatment should be based on regulating the spleen and stomach. In the early stage of DKD, dysfunction of the spleen and stomach leads to the initial generation of internal heat. Common syndrome patterns include gastrointestinal heat accumulation and constrained heat in the liver and stomach, for which modified Gegen Qinlian Decoction (葛根芩连汤) can be used to clear heat bind while modified Dachaihu Decoction (大柴胡汤) is used to clear stomach and soothe liver, respectively. In the middle stage of DKD, weakness of the spleen and stomach results in the initial formation of concretions and conglomerations. Common patterns include spleen deficiency with prevalence of dampness and deficiency of both the spleen and kidney. Treatment emphasizes strengthening the spleen and resolving dampness, raising yang and boosting the stomach with modified Shengyang Yiwei Decoction (升阳益胃汤), or supplementing spleen and boosting kidney, dissipating bind and dispe-ring concretions with modified Shenqi Dihuang Decoction (参芪地黄汤), respectively. In the late stage of DKD, it is characterized by spleen and stomach depletion, and rampant accumulation of turbidity and toxin, and the common syndrome patterns are damp-turbidity obstruction in the middle jiao (焦) and spleen-kidney yang deficiency. Treatment aims to remove turbidity and harmonize the stomach, or to warm the kidney and strengthen the spleen while elimina-ting turbidity, using modified Dahuang Gancao Decoction(大黄甘草汤) and Jupi Zhuru Decoction (橘皮竹茹汤) or modified Baoyuan Decoction (保元汤) and Lizhong Decoction (理中汤), respectively. In clinical practice, appropriate formulas and medications are flexibly selected according to specific syndromes.
4.Effectiveness and safety of coblopasvir hydrochloride combined with sofosbuvir in treatment of chronic hepatitis C
Lifeng CONG ; Ming WEI ; Hongbo CHENG ; Jun HU ; Fang YANG
Journal of Clinical Hepatology 2026;42(8):1831-1837
ObjectiveTo investigate the effectiveness and safety of coblopasvir hydrochloride combined with sofosbuvir (CLP/SOF) in the treatment of patients with chronic hepatitis C (CHC) and those with genotype 3b in terms of virologic response rate, changes in liver and renal function parameters, and adverse events, and to provide a reference for clinical diagnosis and treatment. MethodsThe patients with CHC who were admitted to Maanshan Fourth People’s Hospital from March 1, 2023 to July 31, 2024 were enrolled and treated with CLP/SOF for a course of 12 weeks. Follow-up assessments were conducted at weeks 4, 8, and 12 of treatment and at 12 weeks after the end of treatment, and related data were collected, including HCV RNA, routine blood test results, and liver and renal function parameters. Sustained virologic response at 12 weeks after treatment (SVR12) and safety profile were evaluated. The Friedman test was used for comparison of liver and renal function parameters, routine blood test results, and liver fibrosis score at different time points. ResultsA total of 107 CHC patients treated with CLP/SOF were enrolled, with an age of 22 — 92 years, and there were 55 male patients. The predominant genotypes were 1b (46.73%) and 3b (28.97%). Comorbidities mainly included liver cirrhosis (15 patients), fatty liver disease (27 patients), syphilis (15 patients), HBV infection (8 patients), and HIV infection (2 patients). The overall SVR12 rate was 100% (107/107), with an SVR12 rate of 100% for subgroups with different genotypes and those with liver cirrhosis, fatty liver disease, syphilis, HBV infection, or HIV infection. The patients with HCV genotype 3b comorbid with liver cirrhosis, fatty liver disease, syphilis, HBV infection, hypertension or diabetes also achieved an SVR12 rate of 100%. After CLP/SOF treatment, the patients showed significant reductions in the levels of the liver function parameters alanine aminotransferase, aspartate aminotransferase, total bilirubin, and hemoglobin (all P<0.001) and significant reductions in the liver fibrosis scores fibrosis-4 and aspartate aminotransferase-to-platelet ratio index (both P<0.001). The median creatinine level was 66 μmol/L before treatment, which decreased to 52 μmol/L at week 12 of treatment (P<0.001). No adverse events were reported. ConclusionPatients with CHC achieve a high SVR12 rate and significant improvements in liver function parameters and liver fibrosis markers after treatment with the CLP/SOF regimen, and this regimen has no significant impact on renal function and shows a favorable safety profile. Therefore, it holds promise for clinical application.
5.Effect of interferon induced transmembrane protein 1 ( IFITM1 ) upregulation to cytokine release syndrome in CAR-T-treated B-cell acute lymphoblastic leukemia.
Mengyi DU ; Yinqiang ZHANG ; Chenggong LI ; Fen ZHOU ; Wenjing LUO ; Lu TANG ; Jianghua WU ; Huiwen JIANG ; Qiuzhe WEI ; Cong LU ; Haiming KOU ; Yu HU ; Heng MEI
Chinese Medical Journal 2025;138(10):1242-1244
6.Research progress on the role and mechanism of endothelin-1 in pain.
Cong-Kun HU ; Hao-Jun YOU ; Jing LEI
Acta Physiologica Sinica 2025;77(1):120-130
Endothelin-1 is a peptide derived from endothelial cells, consisting of 21 amino acid residues. In recent years, research has found that endothelin-1 not only plays a key role in vascular tone regulation but also participates in the occurrence and development of various types of pathological pain, including inflammatory pain, neuropathic pain, and cancer pain. Endothelin-1 binds to its receptors and activates multiple signaling pathways such as protein kinase C, calcium ion channels, and the phosphoinositide pathway, thereby influencing neuronal excitability and nociceptive information transmission. This article briefly reviews the current understanding of the mechanisms and potential roles of endothelin-1 in the development of pain, as well as commonly used endothelin-1 receptor antagonists, aiming to provide clues for better utilizing endothelin-1 and its receptors to alleviate and treat pathological pain.
Humans
;
Endothelin-1/physiology*
;
Pain/physiopathology*
;
Signal Transduction/physiology*
;
Animals
;
Neuralgia/physiopathology*
;
Cancer Pain/physiopathology*
;
Endothelin Receptor Antagonists
7.Optimization of fermentation conditions in shake flask of JA20-1, a VOCs-producing biocontrol bacterium and evaluation of its biocontrol effect against Botrytis cinerea of ginseng.
Yu-Ze ZHANG ; Yan-Cong HU ; Xiu-Xiu WANG ; Cong ZHANG ; Zhong-Hua QU ; Bao-Hui LU ; Xue WANG ; Jie GAO
China Journal of Chinese Materia Medica 2025;50(7):1748-1757
Bacillus mycoides JA20-1 was screened and identified as a biocontrol bacterium with a high capacity for producing volatile organic compounds(VOCs) in the laboratory. This strain had significant inhibitory effects on various postharvest disease pathogens in crops, such as Botrytis cinerea, as well as soil-borne disease pathogens in ginseng, such as Sclerotinia ginseng. In order to accelerate its industrialization process, in this study, single-factor experiments and response surface optimization methods were used. The fermentation medium and fermentation conditions in the shake flask of strain JA20-1 were systematically optimized by using cell production volume as the response variable. Meanwhile, the biocontrol effect of JA20-1 on B. cinerea of ginseng during the storage period was evaluated by using the method of fumigation in a dry dish in vitro. The results indicated that the optimal fermentation medium formulation for strain JA20-1 was as follows: 1% yeast paste, 1% soluble starch, 0.25% K_2HPO_4·3H_2O, and 0.2% NaCl. The optimal fermentation conditions in the shake flask were vaccination size of 3%, culture volume of 50 mL in a 250 mL Erlenmeyer flask, pH of 6.2, fermentation temperature of 34 ℃, shaking speed of 180 r·min~(-1), and incubation time of 18 hours. The bacteria count in the fermentation broth under these conditions reached 2.17 × 10~8 CFU·mL~(-1), which was 6.58 times higher than before. The average control efficacy of the fermentation broth on Botrytis cinerea of ginseng under in vitro fumigation reached 61.70% and 84.04% respectively, when 20 mL and 30 mL per dish were used. The research provided theoretical support and technical foundation for the development and utilization of Bacillus mycoides JA20-1 and the biocontrol of soil-borne diseases in ginseng and postharvest diseases in crops.
Botrytis/drug effects*
;
Fermentation
;
Panax/microbiology*
;
Plant Diseases/prevention & control*
;
Volatile Organic Compounds/metabolism*
;
Bacillus/physiology*
;
Pest Control, Biological/methods*
;
Biological Control Agents/metabolism*
;
Culture Media/chemistry*
8."Kidney deficiency-vessel impairment" as core pathogenesis of panvascular diseases: theoretical and clinical perspectives.
Jie WANG ; Jun HU ; Jun LI ; Zhen-Peng ZHANG ; Chao LIU ; Cong CHEN
China Journal of Chinese Materia Medica 2025;50(13):3513-3521
Panvascular disease is a complex systemic disorder. Research by our team has established "kidney deficiency-vascular impairment" as its core pathogenesis. Consequently, we developed a three-tiered progressive prevention and treatment strategy: early prevention phase: focuses on tonifying the kidney and reducing turbidity; mid-term control phase: focuses on tonifying the kidney and stabilizing plaque; late recovery phase: focuses on tonifying the kidney and unblocking collaterals. This targeted therapeutic protocol effectively alleviates clinical symptoms, improves biochemical markers, enhances treatment efficacy, and achieves comprehensive management throughout the disease course. This article systematically elaborates on the concept of "kidney deficiency-vascular impairment" in panvascular disease, summarizes the mechanisms of kidney-tonifying Chinese herbal medicines, aiming to provide a beneficial reference for the whole-course management of panvascular diseases.
Humans
;
Drugs, Chinese Herbal/therapeutic use*
;
Kidney/blood supply*
;
Vascular Diseases/physiopathology*
;
Animals
;
Kidney Diseases/physiopathology*
10.Advances in the regulation of microbial cell metabolism and environmental adaptation.
Yuan LIU ; Guipeng HU ; Xiaomin LI ; Jia LIU ; Cong GAO ; Liming LIU
Chinese Journal of Biotechnology 2025;41(3):1133-1151
The ability of cells to sense and adapt to metabolic changes and environmental variations is essential for their functions. Recent advances in synthetic biology have uncovered increasing mechanisms through which cells detect changes in metabolism and environmental conditions, leading to broader applications. However, a systematic review on the regulation of cellular metabolism and environmental adaption is currently lacking. This article presents a comprehensive overview of this field from three perspectives. First, it introduces key transmembrane and sensor proteins involved in the cellular perception of metabolic and environmental changes. Next, it summarizes the adaptive regulation mechanisms that natural cells employ when confronted with intracellular and extracellular metabolic changes. Finally, the review explores the application scenarios based on cellular adaptive regulation in three aspects: dynamic control, rational metabolic engineering, and adaptive evolution and makes an outlook on the future development directions in this field. This review not only provides a comprehensive perspective on the mechanisms by which cells sense metabolic and environmental variations, but also lays a theoretical foundation for further innovations in the field of synthetic biology. With the continuous advancement of future technologies, a deeper understanding of cellular adaptive regulation mechanisms holds great potential to drive the development and application of novel biomanufacturing platforms.
Adaptation, Physiological
;
Synthetic Biology
;
Metabolic Engineering/methods*
;
Environment
;
Bacteria/genetics*

Result Analysis
Print
Save
E-mail